#USA #Cambridge #Infection Prevention #Next Gen Diagnostics #Karlyn Dauplaise

Next Gen Diagnostics Welcomes Karlyn Dauplaise as CCO

Next Gen Diagnostics (NGD) is excited to announce the appointment of Karlyn Dauplaise as the Chief Commercial Officer for its new division, NGD Infection Prevention. This role places her at the forefront of the organization's mission to revolutionize how hospitals tackle the challenge of infection transmission.

Dauplaise is recognized nationally for her expertise in healthcare strategy and performance enhancement. With a rich background in leading performance improvement initiatives at Vizient, the largest healthcare performance company in the nation, she brings vast experience from collaborating closely with hospital and health system executives. Her focus on optimizing clinical outcomes and implementing innovative technologies aligns perfectly with NGD's goals.

As the CCO, Karlyn will spearhead the commercial strategy, drive market development efforts, and nurture crucial partnerships with customers. One of her primary responsibilities will be to promote the adoption of NGD's automated whole-genome sequencing (WGS) solutions, which enable real-time detection of infection transmission. This cutting-edge technology is crucial in allowing Integrated Delivery Networks (IDNs) to implement genomic surveillance effectively, thereby significantly reducing preventable infections and enhancing patient safety.

Dr. Paul A. Rhodes, Founder and CEO of NGD, expressed his enthusiasm over Dauplaise's joining, stating, "Her profound understanding of health system dynamics and her talent for translating innovation into tangible operations make her an exceptional choice to guide our infection prevention initiatives. Her knowledge and industry connections will be invaluable as healthcare systems increasingly incorporate real-time genomic surveillance into their practices."

Expressing her excitement about her new role, Dauplaise remarked, "I am eager to be part of NGD Infection Prevention at such a critical juncture for the industry. The need for effective tools that minimize harm and empower healthcare teams is more urgent than ever. With NGD's WGS platform, we have a remarkable chance to enable healthcare systems to detect infections sooner and intervene effectively, ultimately improving patient outcomes. I am honored to be a driving force in this transformative endeavor."

About NGD Infection Prevention

NGD Infection Prevention aims to provide hospitals with advanced genomic tools for real-time infection detection, helping to mitigate preventable infections while enhancing overall patient safety and operational efficiencies. The innovative NGD200 system processes multiple samples simultaneously, leveraging minimal hands-on time and integrating automated bioinformatics to deliver actionable insights at affordable costs.

To find out more about NGD and its vision for improving healthcare, visit ngdinfectionprevention.com.

About Next Gen Diagnostics

Next Gen Diagnostics is a trailblazer in biotechnology, dedicated to advancing genomic technologies in healthcare. Beyond its focus on infection prevention, NGD is also developing predictive models to assess antimicrobial resistance, contributing to improved antibiotic decision-making and the future of resistance management. With its headquarters in the United States and laboratories in Cambridge, MA, alongside offices in Boston and Cambridge UK, NGD is well-positioned to lead innovation in healthcare.